The Stanford Cancer Center is applying to the National Cancer Institute (NCI) for five years of funding of a Cancer Center Support Grant (CCSG) and for designation as a Comprehensive Cancer Center. Over the past three years, the Cancer Center has grown from 260 to 311 members representing four Schools within Stanford University (Medicine, Engineering, Humanities and Sciences and Law) and the Northern California Cancer Center with which Stanford has had a long-standing, scientifically productive relationship under a formal affiliation agreement. The CCSG proposal is built upon institutional strengths in technology development, particularly in the fields of imaging, biotechnology, informatics, and chemical engineering. The integration of these research areas into the fields of cancer biology, immunology, genetics and stem cell biology in the development of new approaches to cancer prevention, diagnosis and treatment is the distinguishing feature of this Cancer Center. Ten programs cover the areas of basic, translational/clinical, and population science research in cancer (Cancer Biology, Radiation Biology, Cancer Stem Cells, Cancer Imaging and Early Detection, Molecular Therapeutics, Lymphoma and Hodgkin Disease, Cancer Immunology and Immunotherapy, Hematopoietic Cell Transplantation and Immune Reconstitution, Cancer Epidemiology, and Cancer Prevention and Control). Eleven Shared Resources support the basic and translational/clinical investigation that is carried out in the Center. Based on current NCI base funding of $36 million and with $58 million in other NIH support and $16 million in other peer-reviewed cancer-relevant funding, the Center is requesting $5.3 million in direct costs to support its activities. With the advent of two new buildings for basic and translational research, new recruitment, and increased collaborative interactions, the Center is poised to make significant contributions to cancer research in the new funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA124435-06S1
Application #
8533530
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
2007-06-04
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
6
Fiscal Year
2012
Total Cost
$74,997
Indirect Cost
$27,228
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Lee, Bee L; Fan, Shenghua K; Lu, Ying (2017) A curve-free Bayesian decision-theoretic design for two-agent Phase I trials. J Biopharm Stat 27:34-43
Mohanty, Suchismita; Chen, Zixin; Li, Kai et al. (2017) A Novel Theranostic Strategy for MMP-14-Expressing Glioblastomas Impacts Survival. Mol Cancer Ther 16:1909-1921
Alcántara-Hernández, Marcela; Leylek, Rebecca; Wagar, Lisa E et al. (2017) High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization. Immunity 47:1037-1050.e6
Chao, Mark P; Gentles, Andrew J; Chatterjee, Susmita et al. (2017) Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell 20:329-344.e7
Rogers, Zoë N; McFarland, Christopher D; Winters, Ian P et al. (2017) A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods 14:737-742
Sun, Ruping; Hu, Zheng; Sottoriva, Andrea et al. (2017) Between-region genetic divergence reflects the mode and tempo of tumor evolution. Nat Genet 49:1015-1024
Jin, Yuxue; Lai, Tze Leung (2017) A new approach to regression analysis of censored competing-risks data. Lifetime Data Anal 23:605-625
Clarke, Christina A; Glaser, Sally L; Leung, Rita et al. (2017) Prevalence and characteristics of cancer patients receiving care from single vs. multiple institutions. Cancer Epidemiol 46:27-33
Han, Summer S; Ten Haaf, Kevin; Hazelton, William D et al. (2017) The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. Int J Cancer 140:2436-2443
Wender, Paul A; Hardman, Clayton T; Ho, Stephen et al. (2017) Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV. Science 358:218-223

Showing the most recent 10 out of 227 publications